I-123 whole body scanning: Case report and discussion

Clinical Nuclear Medicine

Volumn 30, Issue 5, 2005, Pages 312-316

  Klein, Herbert A ^a,b,c   DiSibio, Kenneth J ^b   Sims, Diane ^b   Singleton, Helen C ^b   Worthy, Lois J ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Vet Aff Pittsburgh Hlthcare Syst   (United States)

^c Veteran's Affairs Pittsburgh Health System   (United States)

Author keywords

I 123; I 131; Scintigraphy; Thyroid carcinoma; Thyroid stunning

Indexed keywords

IODINE 123; IODINE 131;

ADULT; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CLINICAL FEATURE; DRUG HALF LIFE; HUMAN; LABORATORY TEST; LYMPH NODE METASTASIS; MALE; PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADULT; CARCINOMA, PAPILLARY; HUMANS; IODINE RADIOISOTOPES; MALE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; WHOLE-BODY COUNTING;

EID: 17644378663     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000159526.99677.ed     Document Type: Article

References (30)

1. Freitas JE. Changing concepts in the management of thyroid cancer. In: Freeman LM, ed. Nuclear Medicine Annual 2003. Philadelphia: Lippincott Williams & Wilkins; 2003:101-129.
2. Berbano R, Naddaf S, Echemendia E, et al. Use of iodine-123 as diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer. Endocr Pract. 1998;4:11.
3. Yaakob W, Gordon L, Spicer KM, et al. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. J Nucl Med Technol. 1999;27:279.
4. Mandel SJ, Shankar LK, Bernard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med. 2001;26:6.
5. 123I as diagnostic tracer in patients with well-differentiated thyroid cancer. Endocr Pract. 2001;7:244.
6. 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol. 2001;55:515.
7. 131I therapy whole body scanning. J Clin Endocrinol Metab. 2001;86:5294.
8. Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med. 2002;27:1.
9. 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med. 2002;43:72.
10. 131I for whole-body imaging in thyroid cancer. J Nucl Med. 2002;43:632.
11. Jeevanram RK, Shah DH, Sharma SM, et al. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol. 1986;13:277.
12. Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994;4:49.
13. 131I. Nucl Med Commun 1996;17:839.
14. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun. 1997;18:505.
15. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998;25:242.
16. Muratet JP, Daver A, Minier JF, et al. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998;39:1546.
17. 131I. J Nucl Med. 2000;41:1198.
18. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001;86:3507.
19. Thomas SR, Samaratunga RC, Sperling M, et al. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol. 1993;20:157.
20. Sodium iodide I 123 diagnostic-capsules for oral administration, package insert. Cardinal Health, May 2004.
21. Stabin MG, Stubbs JB, Toohey RE. Radiation Dose Estimates for Radiopharmaceuticals. Oak Ridge, TN: Radiation Internal Dose Information Center, Oak Ridge Institute for Science and Education. NUREG/CR-6345. April 1996.
22. Wellman HN, Anger RT Jr. Radioiodine dosimetry and the use of radioiodines other than I-131 in thyroid diagnosis. Semin Nucl Med. 1971;1:356.
23. Spies WG, Wojtowicz CH, Spies SM, et al. Value of post-therapy whole body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med. 1989;14:793.
24. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629.
25. Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10:573.
26. 123I. Eur J Nucl Med. 2002;29:783.
27. 123I scintigraphy [Letter]. J Nucl Med. 2003;44:852.
28. Lee DJ, Robbins RJ, Turtle RM, et al. I-123 for imaging patients previously treated with radioactive iodine for differentiated thyroid carcinoma and prepared by recombinant human TSH [Abstract]. J Nucl Med. 2004;45:191P.
29. Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499.
30. 131I scanning [Editorial]. J Clin Endocrinol Metab. 2002;87:1486.